drugset / Trial / NCT00463801

Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

NCT00463801

Phase 4 Terminated 52 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults

Timeline

Start
2007-01
Primary completion
2007-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous